Alnylam Pharmaceuticals
ALNY
ALNY
483 hedge funds and large institutions have $28.3B invested in Alnylam Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 83 funds opening new positions, 176 increasing their positions, 147 reducing their positions, and 85 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
2% less first-time investments, than exits
New positions opened: 83 | Existing positions closed: 85
2% less funds holding
Funds holding: 493 → 483 (-10)
14.46% less ownership
Funds ownership: 111.57% → 97.1% (-14%)
Holders
483
Holding in Top 10
14
Calls
$401M
Puts
$318M
Top Buyers
| 1 | +$580M | |
| 2 | +$198M | |
| 3 | +$195M | |
| 4 |
JPMorgan Chase & Co
New York
|
+$138M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$134M |
Top Sellers
| 1 | -$3.8B | |
| 2 | -$162M | |
| 3 | -$135M | |
| 4 |
Amundi
Paris,
France
|
-$119M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$97.1M |